Conclusions: Previous definitions of recurrence and surveillance methods after surgical treatment of nonmelanomaskincancer are variable and nonstandard.
2
Purpose: To identify nonmelanomaskincancer patients with squamous cell carcinoma (SCC) who are at greatest risk of disease-specific mortality.
3
However, there is increasing interest in the use of topical alternatives for the prevention and treatment of nonmelanomaskincancer, particularly superficial variants.
4
Objective: The objective of this study was to learn if variations exist in the treatment of nonmelanomaskincancer in different practice settings.
5
A survey of patients with histologically confirmed nonmelanomaskincancer (NMSC) found 12 families in which several members developed skin cancers.
1
One patient developed squamous cell carcinomaoftheskin.
2
Merkel cell carcinomaoftheskin most commonly presents as a single, rapidly growing, flesh-colored, painless mass.
3
There are a number of options available to the physician for the primary management of basal cell and squamous cell carcinomaoftheskin.
4
Immuno-photodynamic therapy may be particularly indicated for squamous cell carcinomaoftheskin, which we show to be strongly positive for markers of angiogenesis.
5
Carcinomasoftheskin, lip, and uterine cervix were successfully treated by conventional techniques.
1
Multiple or recurrent squamous cell skincarcinoma is a rare tumor in the aged.
2
This is the first case report of scalp PG with cranial osteolysis in an 80-year-old adult, with an initial presentation mimicking skincarcinoma.
3
Mutations in two homologous genes, EVER1 and EVER2 increase the susceptibility to infection with certain human papillomaviruses resulting in high risk of skincarcinoma.
4
Two reports deal with the treatment of progressive squamous cell skincarcinoma with systemic 5-FU, but in only eight patients age less than 70 years.
5
By contrast, cellular senescence was unable to suppress chemically induced skincarcinomas.
Uso de non-melanoma skin cancer en inglés
1
Decreased risks for cervical cancer and non-melanomaskincancer were also seen.
2
The global incidence of non-melanomaskincancer is rising.
3
Cutaneous squamous cell carcinoma (cSCC) is the second most common non-melanomaskincancer worldwide.
4
Objective: To determine the incidence and clinical characteristics of non-melanomaskincancer in Hong Kong Chinese patients.
5
According to the Cancer Council, excluding non-melanomaskincancer, melanoma is the third most common cancer in Australians.
6
Treating superficial non-melanomaskincancer, PDT has been shown to be highly efficient despite the low level of invasiveness.
7
Purpose: Outdoor workers are exposed daily to solar ultraviolet radiation, an important contributor in the development of non-melanomaskincancer.
8
Jha said he doesn't think age should be the determining factor behind who does or doesn't undergo surgery for non-melanomaskincancer.
9
The researchers followed 866 people - mostly older men - being treated for non-melanomaskincancer, which includes basal and squamous cell cancers.
10
Conclusions: These estimates of the burden of non-melanomaskincancer in Canada identify the need for further prevention efforts, particularly in agriculture and construction.
11
Patients: Records of 528 Chinese patients with a histological diagnosis of non-melanomaskincancer from 1990 to 1999 were reviewed.
12
Methods: Fifty-four PWA with lesions suspicious for non-melanomaskincancer sought care at Tanzanian dermatologic clinics from 2017 to 2019.
13
We investigated the XRCC1 arg399gln polymorphism and its interaction with carcinogen exposure in a large, population-based case-control study of non-melanomaskincancer.
14
Results: In 2011, 6.31% (4556 cases) of non-melanomaskincancer cases were estimated to be attributable to occupational exposure to solar ultraviolet radiation.
15
Pigmented basal cell carcinoma was the most common type of non-melanomaskincancer (60.1%) in Chinese patients, in contrast with rodent ulceration in Caucasian.
16
Results: There were an estimated 3.45 million new cases of cancer (excluding non-melanomaskincancer) and 1.75 million deaths from cancer in Europe in 2012.